Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting
Pharvaris announced acceptance of six abstracts (one oral, five posters) at the ACAAI 2026 Annual Scientific Meeting, November 12-16 in Phoenix. The oral presentation features late-breaking data from the pivotal Phase 3 CHAPTER-3 study of oral deucrictibant extended-release tablet for prophylaxis of hereditary angioedema attacks, presented by Marc A. Riedl.
Key figures
- Drug Name
- deucrictibant
- Phase Of Trial
- Phase 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.